These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9567357)

  • 1. Bisphosphonates: structure-activity relations from a clinical perspective.
    Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():61-4. PubMed ID: 9567357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
    Rogers MJ; Xiong X; Brown RJ; Watts DJ; Russell RG; Bayless AV; Ebetino FH
    Mol Pharmacol; 1995 Feb; 47(2):398-402. PubMed ID: 7870050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements for bisphosphonate actions in vitro.
    van Beek E; Hoekstra M; van de Ruit M; Löwik C; Papapoulos S
    J Bone Miner Res; 1994 Dec; 9(12):1875-82. PubMed ID: 7872052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.
    Van Beek E; Löwik C; Que I; Papapoulos S
    J Bone Miner Res; 1996 Oct; 11(10):1492-7. PubMed ID: 8889849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.
    Rogers MJ; Watts DJ; Russell RG; Ji X; Xiong X; Blackburn GM; Bayless AV; Ebetino FH
    J Bone Miner Res; 1994 Jul; 9(7):1029-39. PubMed ID: 7942149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
    Kotsikorou E; Oldfield E
    J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum.
    Brown RJ; van Beek E; Watts DJ; Löwik CW; Papapoulos SE
    J Bone Miner Res; 1998 Feb; 13(2):253-8. PubMed ID: 9495518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
    J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.
    Martin MB; Arnold W; Heath HT; Urbina JA; Oldfield E
    Biochem Biophys Res Commun; 1999 Oct; 263(3):754-8. PubMed ID: 10512752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiresorptive dose-response relationships across three generations of bisphosphonates.
    Sietsema WK; Ebetino FH; Salvagno AM; Bevan JA
    Drugs Exp Clin Res; 1989; 15(9):389-96. PubMed ID: 2630251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, clinical development, and therapeutic uses of bisphosphonates.
    Licata AA
    Ann Pharmacother; 2005 Apr; 39(4):668-77. PubMed ID: 15755793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
    Ghosh S; Chan JM; Lea CR; Meints GA; Lewis JC; Tovian ZS; Flessner RM; Loftus TC; Bruchhaus I; Kendrick H; Croft SL; Kemp RG; Kobayashi S; Nozaki T; Oldfield E
    J Med Chem; 2004 Jan; 47(1):175-87. PubMed ID: 14695831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonates, their mechanism of action and properties useful in the therapy of metabolic bone diseases].
    Fojtík Z; Kandusová M
    Vnitr Lek; 1997 Apr; 43(4):234-7. PubMed ID: 9601843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.